Clinical trial Recruiting at 1 site Observational Ages 18 and up

Gastric emptying in people with type 2 diabetes taking GLP-1 medicines

Official title: Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists

Run by University Hospital, Geneva · NCT07506356 · Data updated 2026-11-12

See if GLP-1 medicines like semaglutide slow stomach emptying in adults with type 2 diabetes and how that may affect anesthesia timing.

More Diabete Type 2 trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment38 (estimated)
SponsorUniversity Hospital, Geneva
Academic / other
Locations1 site (Geneva, Canton of Geneva)
StatusRecruiting
StartedApril 1, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 1, 2026
Trial IDNCT07506356 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with type 2 diabetes who have been treated with a GLP-1 analog for more than three months, are not on insulin, have BMI ≤40, can lie flat and follow instructions, and can attend three visits at the hospital are ideal candidates.

Probably not a fit

People on insulin, with prior gastric surgery, known GI motility disorders, hiatal hernia, BMI >40, inability to stop smoking 12 hours before measurements, or inability to lie down or follow instructions are unlikely to be eligible or benefit from this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project at Geneva University Hospitals will use gastric ultrasound to measure how much food remains in the stomach of people with type 2 diabetes who have been on GLP-1 analogs for more than three months. Thirty-eight participants will attend three ultrasound visits over a seven-day period to track gastric content after routine meals and fasting. People on insulin, with prior gastric surgery or known gastrointestinal motility disorders, or who cannot lie flat or follow instructions are excluded to keep measurements reliable. The goal is to define how long GLP-1 drugs influence gastric emptying so clinicians can make safer decisions about when to stop these medicines before anesthesia.

Why it matters

Potential benefit: If successful, the results could give clear guidance on how long to stop GLP-1 medicines before anesthesia to reduce the risk of pulmonary aspiration.

How similar studies have gone: Previous studies have shown that GLP-1 agonists slow gastric emptying, but specific evidence guiding how long to stop these drugs before surgery is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female/ Male of 18 years old or more
* With Type 2 Diabetes
* Treated with GLP 1 analog for more than 3 months
* Signed consent
* ASA between I and IV

Exclusion Criteria:

* Insuline treatment
* Gastro intestinal motility disorders
* Past gastric surgery
* Hiatal hernia
* Recent trauma
* Inability to be lay down for the exam
* Inability to follow the instructions for the exam (language, dementia)
* BMI \> 40
* Inability to stop smoking 12h before the measures

Where it's running

  • Hôpitaux Universitaires de Genève
    Geneva, Canton of Geneva, Switzerland
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.